Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann,Michael Lauseker,Susanne Saußele,Markus Pfirrmann,S. Krause,H. J. Kolb,Andreas Neubauer,D. K. Hossfeld,Christoph Nerl,A Gratwohl,Gabriela M. Baerlocher,Dominik Heim,Tim H. Brümmendorf,A. Fabarius,Claudia Haferlach,Brigitte Schlegelberger,Marcel Müller,Sabine Jeromin,Ulrike Proetel,K. Kohlbrenner,A. Voskanyan,S. Rinaldetti,Wolfgang Seifarth,B Spieß,Leopold Balleisen,M. C. Goebeler,M. Hänel,Anthony D. Ho,Jolanta Dengler,C. Falge,Lothar Kanz,Stephan Kremers,A. Burchert,M Kneba,Frank Stegelmann,C. A. Köhne,Hans Walter Lindemann,Cornelius F. Waller,Michael Pfreundschuh,Karsten Spiekermann,W.E. Berdel,Lothar Müller,Matthias Edinger,Jiri Mayer,Dietrich W. Beelen,Martin Bentz,H. Link,Bernd Hertenstein,Roland Fuchs,Martin Wernli,F. Schlegel,Rudolf Schlag,M. de Wit,Lorenz Trümper,Holger Hebart,M. Hahn,J. Thomalla,C. Scheid,Philippe Schafhausen,Walter Verbeek,Michael J. Eckart,W. Gassmann,Antonio Pezzutto,M Schenk,Peter Brossart,Thomas Geer,S. Bildat,E. Schäfer,Andreas Hochhaus,Joerg Hasford

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

2017

Rüdiger Hehlmann
Michael Lauseker
Susanne Saußele
Markus Pfirrmann
S. Krause
H. J. Kolb
Andreas Neubauer
D. K. Hossfeld
Christoph Nerl
A Gratwohl
Gabriela M. Baerlocher
Dominik Heim
Tim H. Brümmendorf
A. Fabarius
Claudia Haferlach
Brigitte Schlegelberger
Marcel Müller
Sabine Jeromin
Ulrike Proetel
K. Kohlbrenner
A. Voskanyan
S. Rinaldetti
Wolfgang Seifarth
B Spieß
Leopold Balleisen
M. C. Goebeler
M. Hänel
Anthony D. Ho
Jolanta Dengler
C. Falge
Lothar Kanz
Stephan Kremers
A. Burchert
M Kneba
Frank Stegelmann
C. A. Köhne
Hans Walter Lindemann
Cornelius F. Waller
Michael Pfreundschuh
Karsten Spiekermann
W.E. Berdel
Lothar Müller
Matthias Edinger
Jiri Mayer
Dietrich W. Beelen
Martin Bentz
H. Link
Bernd Hertenstein
Roland Fuchs
Martin Wernli
F. Schlegel
Rudolf Schlag
M. de Wit
Lorenz Trümper
Holger Hebart
M. Hahn
J. Thomalla
C. Scheid
Philippe Schafhausen
Walter Verbeek
Michael J. Eckart
W. Gassmann
Antonio Pezzutto
M Schenk
Peter Brossart
Thomas Geer
S. Bildat
E. Schäfer
Andreas Hochhaus
Joerg Hasford

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Keywords:

Cancer research
Myeloid leukemia
Immunology
Imatinib
Medicine
Surgery
Cytarabine
Relative survival
Hematopoietic stem cell transplantation
imatinib mesylate
Oncology
Leukemia
Survival analysis
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

146

Citations